People: StemCells Inc (STEM.OQ)

STEM.OQ on NASDAQ Stock Exchange Capital Market

0.40USD
28 Aug 2015
Change (% chg)

$0.01 (+3.09%)
Prev Close
$0.39
Open
$0.39
Day's High
$0.43
Day's Low
$0.39
Volume
90,551
Avg. Vol
210,060
52-wk High
$1.57
52-wk Low
$0.31

Search Stocks

Summary

Name Age Since Current Position

John Schwartz

80 1998 Independent Chairman of the Board

Ian Massey

65 2015 President, Chief Operating Officer

Martin McGlynn

69 2015 Chief Executive Officer, Director

Gregory Schiffman

57 2014 Chief Financial Officer, Executive Vice President - Finance

Ann Tsukamoto

62 2013 Executive Vice President - Scientific and Strategic Alliances

Kenneth Stratton

46 2007 General Counsel

Alan Trounson

69 2014 Director

Irving Weissman

75 1997 Director

Eric Bjerkholt

55 2004 Independent Director

R. Scott Greer

56 2010 Independent Director

Ricardo Levy

70 2001 Independent Director

Biographies

Name Description

John Schwartz

Dr. John J. Schwartz, Ph.D., is Independent Chairman of the Board of StemCells, Inc. He is the former President and Chief Executive Officer of Systemix, Inc. Dr. Schwartz is currently the President of Quantum Strategies Management Company, a registered investment advisor located in Palo Alto, California. Prior to his positions at Systemix, he served as Assistant Professor, Vice President and General Counsel at Stanford University in California. Dr. Schwartz graduated from Harvard Law School in 1958 and received his Ph.D. degree in physics from the University of Rochester in 1965.

Ian Massey

Dr. Ian J. Massey, Ph.D. is President, Chief Operating Officer of StemCells, Inc. Dr. Massey has over thirty years of pharmaceutical industry experience in all phases of product development, from pre-clinical research and target selection through drug marketing approval. Most recently, he was the COO and President of U.S. Operations of Biotie Therapies Corporation, a publicly traded Finnish company focused on neurodegenerative and psychiatric disorders. Prior to this, in May 2006, Dr. Massey co-founded Synosia Therapeutics. Under Dr. Massey's leadership as President and CEO, Synosia licensed a portfolio of drug candidates from Novartis, Roche and Syngenta for clinical development as potential therapeutics for the treatment of CNS disorders. Synosia was acquired by Biotie in February 2011. Dr. Massey's career in the pharmaceutical industry has included over 28 years with Syntex Research and then Roche, where he held roles of increasing responsibility including (i) Vice President and Director of Preclinical Research and Development for Roche Bioscience, (ii) Senior Vice President, Head of the Neurobiology Business Unit and Central R&D, Roche Bioscience, and (iii) Senior Vice President, Head of Research and Preclinical Development, Roche Palo Alto. During his time at Roche and Syntex, Dr. Massey directed and/or contributed to the discovery, preclinical testing, and early clinical development of approximately forty New Chemical Entities which entered clinical studies, over twenty of which progressed to Phase II clinical/proof of concept studies. Dr. Massey received his D. Phil Degree in Organic Chemistry from Oxford University and then undertook postdoctoral work first in the Institute of Organic Chemistry at Syntex Research and then with Professor Carl Djerassi at Stanford University.

Martin McGlynn

Mr. Martin M. McGlynn is Chief Executive Officer, Director of the Company. He has spent several decades in the life sciences industry in Europe, Canada and the United States. He began his career with Becton Dickinson, Ireland Ltd., and spent eight years in manufacturing operations. He joined Abbott Labs in 1977 where he held positions as General Manager, Abbott Ireland Ltd., President and General Manager of Abbott Canada Ltd. and Vice President of Abbott International Ltd. In 1990, he joined the BOC Group as President of Anaquest, Inc., a global leader in anesthesia and acute care pharmaceuticals headquartered in New Jersey. Mr. McGlynn joined the biotech industry in 1994 when he became President and Chief Executive Officer of Pharmadigm, Inc., a private, venture capital-backed company engaged in the research and development of a new class of anti-inflammatory agents. Mr. McGlynn is a native of Dublin, Ireland. He holds a Bachelor of Commerce degree from University College, Dublin. He is a former member of the Board of Directors of the Confederation of Irish Industries (CII) and the Pharmaceutical Manufacturers Association of Canada (PMAC), and currently serves as a member of the Board of the Alliance for Regenerative Medicine (ARM).

Gregory Schiffman

Mr. Gregory T. Schiffman has been appointed as Chief Financial Officer, Executive Vice President - Finance of StemCells, Inc., effective January 1, 2014. Mr. Schiffman and the company, dated November 13, 2013, Mr. Schiffman receives an annual base salary of $450,000 per year and a discretionary target bonus of up to 50% of his base salary. Pursuant to Mr. Schiffman’s November 2013 employment agreement, we granted him 350,000 restricted stock units under our 2012 Commencement Incentive Plan. This award will vest over four years, with 25% vesting on each of the first four anniversaries of his employment.

Ann Tsukamoto

Dr. Ann Tsukamoto, Ph.D., is Executive Vice President - Scientific and Strategic Alliances of StemCells, Inc. She was appointed Vice President, Scientific Operations in June 1998; Vice President, Research and Development in February 2002; Chief Operating Officer in November 2006; and Executive Vice President, Research and Development, in October 2008. In June 2013, Dr. Tsukamoto was appointed Executive Vice President, Scientific and Strategic Alliances, with responsibility for developing the Company’s alliances with research institutions, corporations, government agencies, and disease foundations. Dr. Tsukamoto is married to one of our outside directors.

Kenneth Stratton

Mr. Kenneth Stratton, J.D., is General Counsel of StemCells, Inc. In March 2008, he assumed responsibility for the Human Resources function. Prior to joining StemCells, Mr. Stratton served as Deputy General Counsel for Threshold Pharmaceuticals and as Senior Legal Counsel for Medtronic, Inc.’s Vascular business unit.

Alan Trounson

Dr. Alan O. Trounson, Ph.D. is Director of StemCells, Inc. Dr. Trounson has been the recipient of over 30 awards and distinctions for his scientific work, including pioneering work in the fields of in-vitro fertilization and stem cells. As part of his academic research, Dr. Trounson pioneered a new stem cell biology approach for the treatment of a broad range of diseases and injuries, which was awarded the first ever Australian Center of Excellence in Biotechnology grant worth $110 million dollars. Dr. Trounson's previous academic positions include Scientific Director of Monash IVF Pty Ltd., Personal Chair in Stem Cell Science and Director of the Monash Immunology and Stem Cell Laboratories, Deputy Director/Director of the Monash Institute of Reproduction and Development, Director of the Centre of Early Human Development, Facility of Medicine, and Personal Chair of Obstetrics and Gynaecology-Pediatrics at Monash University in Melbourne, Australia. He has founded a number of companies including Infertility Medical Center Pty Ltd./Monash IVF Pty Ltd., IVF Australia Corp/IntegraMed Corp (US), Sydney IVF Pty Ltd./Genea Pty Ltd., Maccine Pte Ltd and the Australian Stem Cell Center Ltd. He established two foundations, the Low Cost IVF Foundation for the treatment of infertile women in Africa and for the treatment of patients with HIV, to avoid vertical transmission to children and the Friends of Low Cost IVF (US). He is returning to Melbourne to continue to support international biotechnology in regenerative medicine.

Irving Weissman

Dr. Irving L. Weissman, M.D., is Director of StemCells, Inc. Dr. Weissman was elected to the Board of Directors in September 1997. He is the Virginia and Daniel K. Ludwig Professor of Cancer Research, Professor of Pathology and Professor of Developmental Biology at Stanford University.

Eric Bjerkholt

Mr. Eric H. Bjerkholt is an Independent Director of StemCells, Inc. Mr. Bjerkholt is a financial expert and currently serves as the Executive Vice President and Chief Financial Officer of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company. His business experience spans more than 20 years, during which time he founded a nutraceutical company and worked as an investment banker. Mr. Bjerkholt currently serves on the board of directors of Round Table Pizza.

R. Scott Greer

Mr. R. Scott Greer is an Independent Director of StemCells, Inc. Mr. Greer was appointed to the Board of Directors in June 2010. He is currently a principal and managing director of Numenor Ventures LLC, which he founded in 2002 to provide funding and strategic advisory services to early stage enterprises. Mr. Greer currently serves as Chairman of Ablexis, a development stage biotechnology company, and he is also on the board of Nektar Therapeutics.

Ricardo Levy

Dr. Ricardo B. Levy, Ph.D., is an Independent Director of StemCells, Inc. Dr. Levy was elected to the Board of Directors in September 2001. He currently serves as a director on the board of Accelrys, Inc., a public company focused on molecular modeling and simulation software for both life and materials science research.

Basic Compensation

Name Fiscal Year Total

John Schwartz

--

Ian Massey

--

Martin McGlynn

832,784

Gregory Schiffman

1,094,110

Ann Tsukamoto

999,533

Kenneth Stratton

442,180

Alan Trounson

--

Irving Weissman

--

Eric Bjerkholt

--

R. Scott Greer

--

Ricardo Levy

--
As Of  30 Dec 2014

Options Compensation

Search Stocks